AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 141 min read$QNRX

Quoin Pharmaceuticals granted EMA orphan drug designation for QRX003; plans first PSS trial

Quoin Pharmaceuticals (QNRX) received EMA Orphan Drug Designation for QRX003, a treatment for Peeling Skin Syndrome. The designation offers regulatory incentives, including market exclusivity. The company plans to start its first formal clinical study for the condition before year-end. QRX003 also has US pediatric rare disease and Fast Track designations.

Original reporting
tradingview.com
Published Oct 14, 2026, 10:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 10:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Quoin Pharmaceuticals granted EMA orphan drug designation for QRX003; plans first PSS trial — source image
Source · tradingview.com
Decision brief

The 30-second read

$QNRXBullishMed
01

Why it matters

The EMA orphan designation provides regulatory incentives and could significantly de‑risk the development path, potentially attracting partnership or financing.

02

Market read

Regulatory milestone for a micro‑cap biotech, likely to generate short‑term buying interest and longer‑term valuation uplift if trials progress.

03

What to watch

The designation does not guarantee approval; execution risk of the clinical program remains high.

Relevance 7/10Novelty 8/10Timing: before year‑end

Background

Quoin Pharmaceuticals is a clinical‑stage biotech focused on rare skin disorders. QRX003 targets Peeling Skin Syndrome, a condition with no approved therapy.

Company-level read

Ticker impact

$QNRXBullishHigh confidence
Context

Quoin Pharmaceuticals received EMA orphan drug designation for QRX003, a new regulatory milestone that can boost the drug's market potential and valuation.

Expected impact

upside pressure as investors price in regulatory incentives and future market exclusivity.

Evidence & confidence

The designation is a primary disclosure for a biotech micro‑cap; such regulatory wins historically trigger share price appreciation.

Market effects

Sector

Strengthens the rare‑disease biotech sector by highlighting EMA support for orphan therapies.

Regional

May improve investor sentiment toward European‑listed biotech pipelines.

Global

Adds to the pipeline of rare‑disease treatments with potential global market exclusivity.

Counterpoint

What could challenge this read

If the upcoming trial fails to meet endpoints, the orphan status may not translate into commercial value.

Key entities

  • Company
    Quoin Pharmaceuticals Ltd.

    Biotech developer of QRX003.

  • Regulator
    European Medicines Agency (EMA)

    Granted orphan drug designation for QRX003.

Read at source← All news

StoryQuoin receives EMA orphan‑drug status for QRX003, paving way for rare‑skin‑disease trial

Also covered by

5 outlets

Related articles

OCT 14
$QNRXMedAI 8/10

Quoin Secures EMA Orphan Drug Designation For QRX003 In Rare Skin Disorder

Quoin Pharmaceuticals (QNRX) received EMA Orphan Drug Designation for QRX003 to treat Peeling Skin Syndrome, a rare skin disorder. The designation offers development incentives and potential market exclusivity. QNRX plans to start clinical trials for PSS by year-end. QRX003 has also received U.S. and Japanese designations for rare diseases. QNRX stock closed at $4.15, down 4.82%.

rttnews.com2 min
OCT 14
$QNRXMedAI 8/10

Quoin Pharmaceuticals Gains EMA Orphan Status for QRX003

Quoin Pharmaceuticals (QNRX) announced that the European Medicines Agency granted Orphan Drug Designation to its lead candidate QRX003 for Peeling Skin Syndrome. This status offers incentives and potential market exclusivity. The company is on track to launch a clinical study by year-end. Analysts have a $14.00 price target, but Spark's AI rates it Neutral due to financial performance and technicals.

tipranks.com2 min
OCT 14
$QNRXHighAI 8/10

Quoin receives EU orphan drug status for peeling skin treatment

Quoin Pharmaceuticals (QNRX) received EU orphan drug status for QRX003, a treatment for Peeling Skin Syndrome, offering benefits like fee reductions and market exclusivity. The company plans a clinical trial by late 2026. QRX003 also has US and Japanese orphan drug designations for Netherton Syndrome, with late-stage trials ongoing. Quoin focuses on rare disease treatments.

investing.com1 min
OCT 14
$QNRXMedAI 8/10

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome – Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug

SEC EDGAR 8-K2 min
OCT 14
$QNRXMedAI 8/10

Europe gives a rare skin disease drug special status. Approval could bring 10 years' exclusivity.

Quoin Pharmaceuticals (QNRX) announced that its lead product QRX003 received Orphan Drug Designation in Europe for treating Peeling Skin Syndrome. This designation provides 10 years of market exclusivity upon approval and includes benefits like fee reductions and access to EU grants. The company plans to initiate the first formal clinical trial for Peeling Skin Syndrome by year-end. QRX003 has also received multiple regulatory designations for Netherton Syndrome in the US, Europe, and Japan.

stocktitan.net2 min